A recent study found that the protective effects against atherosclerosis of atorvastatin, as a commonly used lipid-lowering drug in clinical practice, did not depend on cholesterol-lowering capacity, but on the ability to restrain the pyroptosis of ECs through the lncRNA NEXN-AS1/NEXN pathway (Wu L. M. et al., 2020). The gene discussed is NEXN; the disease is atherosclerosis.